Exact Sciences
5505 Endeavor Lane
Madison
WI
53719
United States
Tel: 608.284.5700
Website: http://www.exactsciences.com/
Email: jobs@exactsciences.com
519 articles about Exact Sciences
-
Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients
1/10/2022
Exact Sciences Corp. and OncXerna Therapeutics, Inc., a precision medicine company, announced they have entered an exclusive license agreement to bring OncXerna's Xerna TME Panel lab services to more U.S. patients.
-
Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients
1/10/2022
Exact Sciences Corp. announced it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing.
-
Exact Sciences to participate in J.P. Morgan Healthcare Conference - Jan 03, 2022
1/3/2022
Exact Sciences Corp. announced that company management will participate in the following virtual conference and invited investors to participate by webcast.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients
11/23/2021
Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the publication of results underscoring the importance of adverse pathology as a reliable and critical endpoint for risk-assessment in clinically low-risk prostate cancer patients.
-
Phillips-Medisize and Exact Sciences Collaborate to Fight Colorectal Cancer
11/3/2021
Phillips-Medisize, a Molex company and leader in drug delivery, diagnostic and MedTech devices, announces the successful collaboration with Exact Sciences, a global leader in cancer diagnostics, to advance early cancer detection.
-
Exact Sciences announces third quarter 2021 results
11/2/2021
Exact Sciences Corp. announced that the company generated revenue of $456.4 million for the third quarter ended September 30, 2021, compared to $408.4 million for the same period of 2020.
-
Exact Sciences to participate in November 2021 investor conferences
11/1/2021
Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.
-
New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening
10/25/2021
Exact Sciences Corp. shared data from modeling analyses that demonstrate Cologuard, with its included patient navigation system, provides a greater reduction in incidence and mortality from colorectal cancer compared to annual fecal immunochemical test, when it included outreach, with or without a mailed annual FIT, using real world adherence rates in a simulated Medicaid population.
-
Exact Sciences schedules third quarter 2021 earnings call
10/8/2021
Exact Sciences Corp. announced that the company plans to release its third quarter 2021 financial results after the close of the U.S. financial markets on November 2, 2021.
-
Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients
9/14/2021
Exact Sciences Corp., a global leader in cancer diagnostics, announced that it has entered into a collaboration agreement with the National Surgical Adjuvant Breast and Bowel Project, a cooperative group founded by the National Cancer Institute.
-
Exact Sciences to participate in September 2021 investor conferences
9/1/2021
Exact Sciences Corp. announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.
-
Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan
8/16/2021
Exact Sciences Corp. announced that Japan's Ministry of Health, Labor and Welfare has approved the Oncotype DX Breast Recurrence Score® Program.
-
Exact Sciences Announces Second Quarter 2021 Results
7/28/2021
Exact Sciences Corp. announced that the company generated revenue of $434.8 million for the second quarter ended June 30, 2021, compared to $268.9 million for the same period of 2020.
-
Exact Sciences schedules second quarter 2021 earnings call
7/8/2021
Exact Sciences Corp. announced that the company plans to release its second quarter 2021 financial results after the close of the U.S. financial markets on July 28, 2021.
-
Exact Sciences to participate in June 2021 investor conferences
5/24/2021
Exact Sciences Corp. announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.
-
Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021
5/19/2021
Exact Sciences Corp., a global leader in cancer diagnostics, announced new data on its cancer tests and treatment guidance tools will be showcased in seven presentations and one e-abstract at the 2021 American Society of Clinical Oncology Annual Meeting, being held virtually June 4-8.
-
Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45
5/19/2021
The United States Preventive Services Task Force released its final colorectal cancer screening recommendation that screening begin at age 45.
-
Promega, Exact Sciences Partnering to Help Jumpstart Colorectal Cancer Screenings
5/10/2021
Serious runners and casual walkers alike are invited to join a month-long Get Your Rear in Gear® - Madison run/walk virtual event during May to raise money and awareness for colorectal cancer screening efforts.
-
Exact Sciences Announces First Quarter 2021 Results
5/4/2021
Exact Sciences Corp. announced that the company generated revenue of $402.1 million for the first quarter ended March 31, 2021, compared to $347.8 million for the same period of 2020.